Skip to main content

Ordentlich Peter's Form 4 filing

Syndax Pharmaceuticals Inc (SNDX) · filed Dec 2, 2022

Accession no.
0001562180-22-008017
Filed
Dec 2, 2022
Trade date
Dec 1-2, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $625.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ordentlich PeterCIK 0001594274Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2022Common StockMOption exerciseAcquired+3,772$6.35+$23,952.24,037Direct
Dec 1, 2022Common StockSSaleDisposed−3,772$25.01−$94,337.72265Direct
Dec 1, 2022Common StockMOption exerciseAcquired+4,028$6.38+$25,698.644,293Direct
Dec 1, 2022Common StockSSaleDisposed−4,028$25.01−$100,740.28265Direct
Dec 2, 2022Common StockMOption exerciseAcquired+17,200$6.38+$109,73617,465Direct
Dec 2, 2022Common StockSSaleDisposed−17,200$25.05−$430,860265Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 1, 2022Common StockMOption exerciseDisposed−4,028$0.00$00Direct
Dec 1, 2022Common StockMOption exerciseDisposed−3,772$0.00$00Direct
Dec 2, 2022Common StockMOption exerciseDisposed−17,200$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)